Yuekang Pharmaceutical announced that YKYY036 injections from the company's subsidiaries Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. and Yuekang Pharmaceutical Group Hangzhou Tianlong Pharmaceutical Co., Ltd. recently obtained clinical trial approval notices from the State Drug Administration; the drug from Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd. was also approved for clinical trials by the US FDA. YKYY036 injection is a self-developed siRNA drug targeting INHBE's new metabolic regulation target. This approval is a phased achievement in the development of a new drug. It will not have a significant impact on the company's recent performance, and there is uncertainty about subsequent R&D and approval results.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.